EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Triapine An inhibitor of ribonucleotide reductase with antineoplastic activity



Triapine An inhibitor of ribonucleotide reductase with antineoplastic activity



Weber, G Advances in Enzyme Regulation : 3-12




(PDF 0-2 workdays service: $29.90)

Accession: 035985969

Download citation: RISBibTeXText



Related references

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Advances in Enzyme Regulation 39: 3-12, 1999

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochemical Pharmacology 59(8): 983-991, 2000

Short-term toxicological evaluation in Triapine (3-amino-pyridine-2-carboxaldehyde thiosemicarbazone or 3-AP), a ribonucleotide reductase inhibitor with potential antitumor activity, in dogs and rats. International Journal of Toxicology 19(2): 85-93, 2000

Phase I Study of Triapine , a Novel Ribonucleotide Reductase Inhibitor , in Patients with Refractory Hematologic Malignancies. Blood 100(11): Abstract No 3034, November 16, 2002

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research 27(12): 1077-1083, 2003

The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochemical Pharmacology 73(10): 1548-1557, 2007

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clinical Cancer Research 12(9): 2912-2918, 2006

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leukemia Research 31(9): 1165-1173, 2007

Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry. Biomedical Chromatography 29(9): 1380-1387, 2016

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clinical Cancer Research 9(11): 4092-4100, 2003

FMdC Antineoplastic ribonucleotide-diphosphate reductase inhibitor. Drugs of the Future 24(5): 502-510, 1999

Amidox nsc 343341 vf 236 antineoplastic ribonucleotide reductase inhibitor. Drugs of the Future 16(11): 990-991, 1991